The impact of long-term aspirin use on the patients undergoing shoulder arthroplasty

Mao, Xiuhua; Liang, Chen; Li, Xiaoqin; Shi, Danping; Yang, Qinfeng; Xie, Hao; Liang, Fangguo; Cui, Yuhui

doi:10.1186/s13018-023-04374-4

Journal of Orthopaedic Surgery and Research

Table 1 Demographic and comorbidities characteristic of study cohorts

From: The impact of long-term aspirin use on the patients undergoing shoulder arthroplasty

Demographic/comorbidity	Study cohorts
Demographic/comorbidity	L-AU^a N = 22,643 %	Whole non-L-AU N = 139,759 %	p value	Matched non-L-AU N = 22,643 %	p value	SMD^b after Matching (L-AU & matched non-L-AU)
Gender (%)			< 0.001		0.652
Male	48.60	42.40		48.30		0.005
Female	51.40	57.60		51.70		0.005
Age (Mean ± SD)^c	71.11 ± 8.41	68.49 ± 10.01	< 0.001	71.15 ± 8.48	0.994	0.009
Age subgroup (%)			< 0.001		0.433
18–44	0.30	1.80		0.30
45–54	2.70	6.50		2.50		0.017
55–64	17.20	22.90		17.60		0.001
65–74	44.30	40.40		44.30		0.002
≥ 75	35.40	28.40		35.40		0.007
Race (%)			< 0.001		0.969
White	85.00	82.80		85.20
Black	3.80	4.40		3.90		0.001
Hispanic	2.70	3.80		2.60		0.008
Asian or pacific islander	0.40	0.50		0.40		0.002
Native American	0.30	0.40		0.30		0.001
Other	1.40	1.60		1.40		0.010
Missing	6.30	6.60		6.30		0.004
Pay type (%)			< 0.001		0.806
Medicare	75.00	67.20		75.20
Medicaid	2.00	3.30		2.00		0.006
Private insurance	19.1	24.50		19.10		0.009
Self-pay	0.30	0.50		0.30		0.008
No charge	0.00	0.10		0.00		0.006
Other	3.60	4.50		3.40		0.010
Hospital bed size (%)			0.001		0.680
Small	27.20	26.40		26.90
Medium	26.60	26.10		26.90		0.010
Large	46.20	47.50		46.20		< 0.001
Hospital location (%)			0.202		0.716	0.012
Rural	91.10	91.30		91.20
Urban	8.90	8.70		8.80
Hospital teaching status (%)			< 0.001		0.791	0.005
Teaching	64.10	59.20		64.00
Non-teaching	35.90	40.80		36.00
Pre-existing comorbidity (%)
Hypertension	78.40	64.60	< 0.001	78.50	0.784	0.003
Obesity	22.40	17.50	< 0.001	22.80	0.357	< 0.001
Uncomplicated diabetes mellitus	19.90	15.90	< 0.001	20.10	0.557	0.012
Hypothyroidism	18.50	16.60	< 0.001	18.30	0.680	0.004
Chronic lung disease	19.40	18.40	< 0.001	19.70	0.400	0.002
Depression	19.60	15.70	< 0.001	16.70	0.538	0.009
Deficiency anemia	4.00	4.50	0.003	3.90	0.549	0.004
Fluid and electrolyte disorders	5.60	5.30	0.074	5.70	0.555	0.004
Renal failure	8.20	5.80	< 0.001	8.20	0.732	0.007
Valvular disease	5.00	3.10	< 0.001	5.20	0.380	0.005
Other neurological disorders	2.70	3.10	0.001	2.60	0.681	0.001
Rheumatoid arthritis	4.90	5.30	0.014	5.20	0.133	0.006
Peripheral vascular disorders	4.10	2.30	< 0.001	3.90	0.144	0.011
Congestive heart failure	4.60	3.10	< 0.001	4.50	0.804	0.005
Complicated diabetes mellitus	7.50	3.70	< 0.001	7.20	0.172	0.012
Coagulopathy	1.20	1.30	0.231	1.30	0.866	0.003
Psychoses	2.20	2.40	0.050	2.10	0.383	0.004
Chronic blood loss anemia	0.40	0.50	0.463	0.40	0.516	0.011
Pulmonary circulatory disease	1.10	0.80	< 0.001	1.10	0.529	< 0.001
Alcohol abuse	1.20	1.30	0.245	1.20	0.634	0.014
Liver disease	1.60	1.80	0.056	1.70	0.421	0.007
Solid tumor without metastasis	0.60	0.60	0.667	0.70	0.228	0.001
Drug abuse	0.70	0.80	0.015	0.60	0.816	0.001
Lymphoma	0.20	0.30	0.340	0.30	0.779	0.004
Paralysis	0.30	0.40	0.011	0.30	0.266	0.005
Weight loss	0.20	0.30	0.089	0.20	0.844	0.004
Metastatic cancer	0.20	0.20	0.164	0.20	1.000	0.007
Peptic ulcer disease excluding bleeding	0.20	0.20	0.013	0.30	0.703	0.005
Acquired immune deficiency syndrome	0.10	0.20	0.014	0.10	0.622	0.003
Charlson comorbidity index subgroup (%)			< 0.001		0.648
0	0.10	0.60		0.10
1	0.50	2.20		0.40		0.019
2	4.50	9.40		4.40		0.009
≥ 3	94.90	87.70		95.10		0.014

^aL-AU: long-term aspirin use
^bSMD: standardized mean difference
^cSD: standard difference

Back to article page

ISSN: 1749-799X

Contact us

Submission enquiries: journalsubmissions@springernature.com